Mayo Clinic, Oxford Nanopore partner to develop novel clinical tests for cancer and genetic disorders
Within the framework of the collaboration, Mayo Clinic and Oxford Nanopore have identified several key areas of development,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Oct 23
Within the framework of the collaboration, Mayo Clinic and Oxford Nanopore have identified several key areas of development,…
20 Oct 23
Aspen plans to initiate a first-in-patient Phase 1/2a clinical trial of ANPD001 for participants with moderate to severe…
19 Oct 23
Nuvaxovid is a protein-based ready-to-use vaccine developed by creating copies of the surface spike protein of SARS-CoV-2, a…
19 Oct 23
The approval is based on results from three Phase 3 clinical trials in which antibody delivered fast, complete…
19 Oct 23
SUANFARMA, through its R&D division, celebrates the historic agreement reached with Reyoung Pharmaceutical, a leader in the manufacture of…
19 Oct 23
During a plenary lecture at the 26th World Congress of Neurology, Dr. Anthony Lang, professor of neurology and Jack Clark…
18 Oct 23
Xphozah is a single tablet, twice daily inhibitor with a differentiated mechanism of action that blocks phosphate absorption…
18 Oct 23
The approval was based on the safety and efficacy data from the RAISE phase 3 study in which…
17 Oct 23
Ocedurenone is currently being evaluated in the phase 3 CLARION-CKD trial in patients with uncontrolled hypertension and advanced…
17 Oct 23
EDIT-301 is an investigational, gene editing medicine which consists of patient derived CD34+ hematopoietic stem and progenitor cells…